Exploring the Impact of GLP-1 Drugs on Weight Loss, Diabetes, and Potential Addiction
Recent research suggests that GLP-1 medications may not only aid in weight loss and diabetes management but also reduce the risk of substance use disorders and breast cancer in women.
GLP-1 drugs, such as Ozempic, have gained attention for their effectiveness in managing diabetes and promoting weight loss. Recent studies indicate that these medications may also have implications for addiction treatment.
One study found that individuals using GLP-1 medications were less likely to receive a diagnosis of substance use disorder, suggesting a potential protective effect against addiction.
Additionally, research indicates that women taking GLP-1 drugs may experience a 30% lower risk of developing breast cancer. While these findings are promising, they are not definitive proof of causation.
Updates
Update at 13:28 UTC on 2026-06-06
ScienceDaily reported A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer. Researchers say the findings are promising but not yet proof, and c.
Sources: ScienceDaily